文献速递骨质疏松与代谢性骨病

长期口服双膦酸盐停药后骨转换标志物与骨密度的早期变化:事后分析

Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis.
PubMed 文献 · Osteoporos Int · 2021-02-19

该事后分析基于随机双盲试验,纳入绝经后骨质疏松女性,比较继续每周阿仑膦酸钠70mg与安慰剂者停药后1-12个月变化。12个月时安慰剂组腰椎、全髋、股骨颈骨密度均低于继续用药组,骨转换标志物早期即升高,提示停药后应监测骨密度。

要点

  • 停用长期阿仑膦酸钠后1-3个月骨转换标志物即升高并持续至12个月。
  • 12个月时安慰剂组腰椎、全髋、股骨颈骨密度均显著低于继续用药组。
  • 基线骨转换标志物较高者股骨颈骨密度下降更明显,需考虑监测。

核心结论

  • 停用长期阿仑膦酸钠后早期即可出现骨转换标志物升高和骨密度下降。
  • 需进一步明确双膦酸盐停药后骨丢失风险相关因素以指导治疗决策。

研究设计与样本

  • 随机双盲试验的事后分析,试验注册号NCT00996801。
  • 对象为绝经后骨质疏松女性,此前口服双膦酸盐≥3-4年且筛查前12个月用阿仑膦酸钠。
  • 继续阿仑膦酸钠70mg/周组87例,安慰剂组88例。

主要发现

  • 12个月时安慰剂组与阿仑膦酸钠组最小二乘均值骨密度变化:腰椎-0.36%对1.29%,全髋-1.44%对0.46%,股骨颈-1.26%对-0.08%(均P<0.05)。
  • 安慰剂组骨转换标志物在1-3个月升高并持续至12个月,与阿仑膦酸钠组比较P<0.001。
  • 基线uNTx/Cr较高(P<0.01)或P1NP较高(P<0.05)的安慰剂亚组股骨颈骨密度下降更明显。
  • 基线年龄较轻和腰椎骨密度较高与12个月腰椎骨密度下降更多相关(P=0.04和P<0.01)。
  • 基线股骨颈骨密度较高预测股骨颈骨密度下降更多(P=0.04)。

临床怎么用

  • 长期口服双膦酸盐停药后应早期监测骨转换标志物和骨密度。
  • 对基线骨转换标志物较高或骨密度较高者,停药后骨丢失风险可能更高。

局限性

  • 为事后分析,结果需进一步研究验证。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This post hoc analysis of a randomized, double-blind study of postmenopausal women with osteoporosis found that there were early increases in bone turnover markers and decreases in bone mineral density after discontinuation of long-term alendronate. These findings might help guide treatment decisions, including monitoring after alendronate withdrawal. INTRODUCTION: The short-term effects of discontinuing long-term bisphosphonates are poorly characterized. This post hoc analysis investigated 1-12-month changes in bone mineral density (BMD) and bone turnover markers (BTM) after alendronate (ALN) discontinuation. METHODS: Data were from a randomized, double-blind trial of MK-5442 (calcium-sensing receptor antagonist) following oral bisphosphonates, with placebo and continued ALN controls ( ClinicalTrials.gov NCT00996801). Postmenopausal women with osteoporosis had received oral bisphosphonate (≥ 3-4 preceding years; ALN for the 12 months pre-screening), continuing on ALN 70 mg/week (n = 87) or placebo (n = 88). RESULTS: At 12 months, least-squares mean percent changes from baseline BMD (placebo vs. ALN) were lumbar spine (LS): - 0.36 vs. 1.29, total hip: - 1.44 vs. 0.46, and femoral neck (FN): - 1.26 vs. - 0.08 (all P < 0.05). BTM levels increased by 1-3 months, to 12 months, with placebo vs. ALN (P < 0.001). FN BMD decline was greater in the placebo subgroup with higher urinary N-terminal cross-linked telopeptides of type I collagen/creatinine [uNTx/Cr] (P < 0.01), and higher serum N-terminal pro-peptide of type 1 collagen [P1NP] levels (P < 0.05), at baseline. There was a trend toward greater FN BMD loss with higher BTM levels at 3 and/or 6 months. Younger age and higher LS BMD at baseline were associated with greater LS BMD loss at 12 months (P = 0.04 and < 0.01, respectively); higher baseline FN BMD predicted greater FN BMD loss (P = 0.04). CONCLUSION: Early changes in BTM levels and BMD were observed after discontinuation of long-term ALN. Further characterization of factors associated with patients' risk of bone loss upon bisphosphonate discontinuation is warranted.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Saag K, Cosman F, De Villiers T, et al. Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis. Osteoporos Int. 2021. PMID: 33606045. doi:10.1007/s00198-020-05785-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。